AU2915801A - In vivo treatment of joint disease using interleukin-1 receptor antagonists - Google Patents

In vivo treatment of joint disease using interleukin-1 receptor antagonists Download PDF

Info

Publication number
AU2915801A
AU2915801A AU29158/01A AU2915801A AU2915801A AU 2915801 A AU2915801 A AU 2915801A AU 29158/01 A AU29158/01 A AU 29158/01A AU 2915801 A AU2915801 A AU 2915801A AU 2915801 A AU2915801 A AU 2915801A
Authority
AU
Australia
Prior art keywords
joint
mammal
viral particles
interleukin
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29158/01A
Other languages
English (en)
Inventor
David D. Frisbie
C. Wayne Mcillwraith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colorado State University Research Foundation
Original Assignee
Colorado State University Research Foundation
Colorado State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colorado State University Research Foundation, Colorado State University filed Critical Colorado State University Research Foundation
Publication of AU2915801A publication Critical patent/AU2915801A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU29158/01A 1999-09-07 2000-09-06 In vivo treatment of joint disease using interleukin-1 receptor antagonists Abandoned AU2915801A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15270799P 1999-09-07 1999-09-07
US60152707 1999-09-07
PCT/US2000/040823 WO2001025435A2 (fr) 1999-09-07 2000-09-06 Traitement in vivo de la maladie des articulations utilisant des antagonistes de recepteurs d'interleukine-1

Publications (1)

Publication Number Publication Date
AU2915801A true AU2915801A (en) 2001-05-10

Family

ID=22544064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29158/01A Abandoned AU2915801A (en) 1999-09-07 2000-09-06 In vivo treatment of joint disease using interleukin-1 receptor antagonists

Country Status (4)

Country Link
EP (1) EP1210432A2 (fr)
AU (1) AU2915801A (fr)
HK (1) HK1044022A1 (fr)
WO (1) WO2001025435A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1729810T3 (en) 2004-04-02 2018-12-03 Swedish Orphan Biovitrum Ab Publ PROCEDURE FOR REDUCING AGGREGATION OF IL-1RA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747072A (en) * 1993-07-30 1998-05-05 University Of Michigan Adenoviral-mediated gene transfer to synovial cells in vivo
JPH1077298A (ja) * 1996-09-05 1998-03-24 Nippon Seibutsu Kagaku Kenkyusho 馬インターロイキン−１レセプターアンタゴニスト

Also Published As

Publication number Publication date
WO2001025435A2 (fr) 2001-04-12
EP1210432A2 (fr) 2002-06-05
HK1044022A1 (zh) 2002-10-04
WO2001025435A3 (fr) 2001-10-18

Similar Documents

Publication Publication Date Title
US20030091536A1 (en) In vivo treatment of joint disease using interleukin-1
AU775245B2 (en) Methods for treatment of degenerative retinal diseases
CA2701215C (fr) Therapie genique de cartilage articulaire utilisant un vecteur recombine codant pour bmp-7
JPH06508039A (ja) 抗腫瘍治療のためのサイトカインを発現する組換え型欠損アデノウイルス
CN110420331B (zh) Alkbh5抑制物在治疗病毒感染性疾病中的应用
CA2149763A1 (fr) Facteur de stimulation des cellules souches de lymphocytes b
CN102170783A (zh) 视网膜细胞存活的HDAC4、HDAC5、HDAC6、HDAC7和HIF1α调节
KR20130094337A (ko) 개량형 이듀로네이트-2-설파타제 및 이의 용도
CN1239510A (zh) 用髓先祖抑制因子－1、单核细胞集落抑制因子和巨噬细胞抑制因子－4治疗疾病的组合物和方法
CN111936172A (zh) 用于治疗视网膜病症的组合物和方法
JP2012065663A (ja) リンパ球系・血球系細胞へ遺伝子導入するためのプロモーターおよびその利用方法
AU2002367534A1 (en) Use of il-19, il-22 and il-24 to treat hematopoietic disorders
WO2022057904A1 (fr) Association d'un virus oncolytique et de cellules immunitaires modifiées pour le traitement de tumeurs
CN101374853B (zh) 用新型腺病毒治疗癌症的方法和组合物
CN114381465B (zh) 优化的cyp4v2基因及其用途
CN109337928B (zh) 通过过表达腺相关病毒受体提高基因治疗效率的方法
AU2915801A (en) In vivo treatment of joint disease using interleukin-1 receptor antagonists
JP2023552535A (ja) 異種導入遺伝子の発現を制御するためのオーファンモチーフ（ｏｒｐｈａｎ ｍｏｔｉｆ）とＣｐＧ密度との組み合わせの使用
Janouskova et al. Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection
CA2999279A1 (fr) Expression ciblee de canaux chlorure et procedes d'utilisation de celle-ci
JPH09510357A (ja) 酸性繊維芽細胞成長因子（ａＦＧＦ）をコードする組み換えアデノウィルス
CN112426523A (zh) 一种含抗病毒组合物的猪用疫苗和应用
CN113018424A (zh) Cst1在预防和/或治疗肝脏免疫失调疾病中的应用
CN1094974C (zh) 表达人白细胞介素12的重组腺病毒及其制法和用途
EP0879294B1 (fr) Cellules souches hematopoietiques transduites